AbbVie in pact with Umoja to develop CAR-T cell therapies seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Health News Roundup: Merck-Eisai s uterine cancer therapy combo fails first-line treatment trial; WHO says more contaminated medicinal syrups found in new regions and more devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.
AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said. North Chicago, Illinois-based AbbVie said late Wednesday it would buy Cerevel for $8.7 billion, gaining a portfolio of drugs being tested for a range of neurological conditions, including emraclidine for schizophrenia. "Boldly buying Cerevel now avoids a possible bidding war post-data," Stifel analysts wrote in a note.
AbbVie s decision to buy
Cerevel Therapeutics before key data on the drug
developer s experimental schizophrenia treatment may have helped
it avoid a potential bidding war but comes with several.